HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IOVA
Iovance Biotherapeutics, Inc.
There isn't enough reported data to score IOVA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IOVA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IOVA's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IOVA PE Valuation
IOVA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IOVA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IOVA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
IOVA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus IOVA down 179%.
IOVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$1.18 | +$0.32 |
| Q2 2025 | -$1.21 | +$0.47 |
| Q1 2025 | -$1.22 | +$0.59 |
| Q4 2024 | -$1.28 | +$0.61 |
| Q3 2024 | -$1.50 | +$0.58 |
| Q2 2024 | -$1.68 | +$0.57 |
| Q1 2024 | -$1.81 | +$0.60 |
| Q4 2023 | -$1.89 | +$0.60 |
IOVA is still losing money, but far less than before: $1.18 per share over the past year, against $2.49 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IOVA on profitability, with a higher operating margin.
IOVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $121.5M | +80% |
| Q2 2026 | $99.3M | +66% |
| Q1 2026 | $71.4M | +45% |
| Q4 2025 | $86.8M | +18% |
| Q3 2025 | $67.5M | +15% |
| Q2 2025 | $60M | +93% |
| Q1 2025 | $49.3M | +6798% |
| Q4 2024 | $73.7M | +15189% |
IOVA has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | +121 points |
| Q2 2026 | -52% | +138 points |
| Q1 2026 | -113% | +132 points |
| Q4 2025 | -85% | +33 points |
| Q3 2025 | -141% | +11 points |
| Q2 2025 | -190% | +138 points |
| Q1 2025 | -246% | +16219 points |
| Q4 2024 | -117% | +25039 points |
IOVA's operating margin was −20% last quarter, up 121 points from the same quarter a year ago, near the top of its range since 2023.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IOVA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IOVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.2M | +$80.3M |
| Q2 2026 | -$66.3M | +$8.6M |
| Q1 2026 | -$78.7M | +$31.2M |
| Q4 2025 | -$61.9M | +$15.6M |
| Q3 2025 | -$89.5M | -$28.3M |
| Q2 2025 | -$74.9M | +$24M |
| Q1 2025 | -$109.9M | +$16.5M |
| Q4 2024 | -$77.5M | +$10M |
IOVA has burned cash in almost every quarter: −$216M over the past year, against −$352M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IOVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IOVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +71% | +190M shares |
| 1 year | +113% | +242M shares |
IOVA has 456M diluted shares, up 113% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IOVA Net Leverage
IOVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IOVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 30.4 | Neutral |
IOVA's weekly RSI is 48 (neutral) and its Stochastic is 30 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IOVA PE vs Healthcare Sector
IOVA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IOVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 33% below |
| 20 week MA | $8.58 | 11% below |
| 50 week MA | $5.43 | 41% above |
| 100 week MA | $4.36 | 75% above |
| 200 week MA | $6.37 | 20% above |
IOVA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IOVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.8 | $49.6 | +78% |
| 2021 | $49.6 | $20.2 | -59% |
| 2022 | $20.2 | $6.12 | -70% |
| 2023 | $6.12 | $8.13 | +33% |
| 2024 | $8.13 | $7.37 | -9.3% |
| 2025 | $7.37 | $2.85 | -61% |
| 2026 YTD | $2.85 | $7.63 | +168% |
IOVA has the edge over HIMS on returns for 2026, with the stronger performance.